According to the Food and Drug Administration (FDA), boosters targeting Omicron are slated to be available starting in fall 2022. The FDA has also recommended a BA.4 and BA.5 component be included in this booster.
Moderna has announced that its Omicron booster yields a significantly higher neutralizing antibody response to BA.4 and BA.5 than its current booster.
Pfizer-BioNTech stated that, compared with their current booster, their Omicron booster gave higher levels of neutralizing antibodies against BA.1. Neutralizing antibodies for BA.4 and BA.5 were present but to a lesser extent.